Skip to content
Back to search results

Asthma Control Test

Introduced by
Robert A. Nathan et al.
Year
2004
Type
Self-report symptom control questionnaire
Family
Respiratory and Allergic Disease
Font size

What does it do?

The ACT is a simple, rapid, patient-centered measure of asthma control.

Developed by Robert Nathan and colleagues in 2004, this 5-item questionnaire quantifies how asthma symptoms, activity limitation, and nighttime awakening affect daily life. It is the most widely used asthma control measure in clinical practice and is recommended by major asthma guidelines as a standard assessment tool.

The intuition behind the method

Well-controlled asthma means normal lung function and minimal symptoms during daily life and night. Yet patients often accept chronic cough, activity avoidance, or sleep disruption as 'normal asthma,' and clinicians may overlook these impacts while focusing on spirometry alone. The ACT asks directly: How often do your asthma symptoms occur during the day or at night? How often did your asthma prevent normal activity? This patient perspective guides medication adjustment decisions: a low ACT score signals need for treatment intensification, even if spirometry appears stable. Conversely, a high ACT score (good control) may justify maintaining or reducing therapy safely.

History

The ACT was developed in 2004 by Robert A. Nathan and colleagues, published in Allergy and Asthma Proceedings. It emerged from the need for a brief, practical asthma control measure suitable for primary care and non-specialist settings, where longer questionnaires (e.g., Asthma Control Questionnaire, ACQ) were perceived as burdensome. The ACT underwent rigorous development involving item selection, cognitive interviews, and validation in diverse asthma populations (mild-moderate and severe, children and adults, various ethnicities). A pediatric version (cACT, 7 items) was developed subsequently. The ACT is now recommended by major asthma guidelines (Global Initiative for Asthma, National Asthma Education Prevention Program) as a standard control assessment tool, with ACT cutoff integrated into asthma severity and risk classification schemes.

When to use it

The ACT is indicated for assessing asthma control in all asthma patients. Use cases include baseline assessment to quantify control and guide initial treatment, monitoring at each clinical visit (quarterly or more frequently for uncontrolled asthma) to track response and inform therapy adjustments, identifying patients at risk for exacerbation (low ACT predicts future exacerbations), outcome assessment in clinical trials as a primary or co-primary endpoint, and quality improvement in asthma care. The ACT is valuable in both primary care (screening for inadequate control) and specialty asthma clinics (monitoring treatment efficacy). A pediatric ACT (cACT, 7 items) exists for children 4-11 years; the standard ACT applies to ages 12 and older.

Limitations and considerations

  • Symptom-based only—does not measure objective lung function (FEV1), airway hyperresponsiveness, or inflammation; spirometry and allergy/inflammation markers must be assessed separately
  • Does not diagnose asthma—measures control in presumed asthma; cannot establish diagnosis, which requires clinical history and objective evidence (spirometry, peak flow variability, bronchial challenge test)
  • Limited discriminant specificity—cannot distinguish asthma control from control of other conditions (e.g., GERD-induced cough, vocal cord dysfunction presenting as dyspnea). Clinical assessment must confirm asthma diagnosis.
  • Potential response bias—patients may under-report symptoms if they minimize disease severity or fear medication escalation; conversely, may over-report if seeking validation or treatment intensification
  • Does not assess exacerbation frequency directly—while low ACT predicts future exacerbations, a single ACT score does not reveal past exacerbation history; must ask separately

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Exceptional brevity—5 items, 1-2 minute completion, fits seamlessly into any clinic workflow, increasing likelihood of routine use
  • Strong psychometric properties—extensively validated in diverse asthma populations with demonstrated internal consistency (Cronbach's α 0.80-0.90), test-retest reliability (ICC 0.80-0.95), and responsiveness to treatment
  • Clinically meaningful cutoff—ACT ≥20 clearly indicates controlled asthma; <20 signals need for action, guiding treatment escalation decisions
  • Predicts exacerbation risk—low baseline ACT predicts asthma exacerbations within 3-6 months, enabling early intervention in high-risk patients
  • Free and universally accessible—no licensing restrictions; available in multiple languages via asthma societies (Global Initiative for Asthma, American Academy of Allergy Asthma & Immunology)
  • Pediatric and adult versions—cACT (ages 4-11) and standard ACT (ages 12+) enable longitudinal assessment across the lifespan

Applications

  • Routine asthma monitoring: In primary care, ACT administered at every visit enables rapid identification of poorly controlled asthma (ACT <20) and guides medication adjustment; studies show ACT-guided management improves outcomes compared to clinician-assessed control alone.
  • Exacerbation prediction: A prospective study showed baseline ACT <20 predicted moderate-severe asthma exacerbations in the following 6 months with 70% sensitivity, enabling proactive intervention (inhaled corticosteroid optimization, asthma action plan review) in high-risk patients.
  • LTRA efficacy: A randomized trial of leukotriene receptor antagonist (LTRA) versus placebo added to inhaled corticosteroid showed ACT improvement (mean +3 points) in the LTRA group, supporting LTRA as add-on therapy in uncontrolled asthma.
  • Asthma action plan adherence: A quality improvement study found patients achieving ACT ≥20 were 3x more likely to have a written asthma action plan and use it correctly, suggesting that good control supports self-management behavior.

How it works

How it works

1

The ACT comprises 5 items: Activity limitation due to asthma, shortness of breath frequency, nighttime symptoms frequency, daytime symptoms frequency, and overall asthma control. Each item uses a 5-point Likert scale (e.g., 1=all of the time, 5=not at all or only 2 days). It is self-administered, typically completed in 1-2 minutes. Paper and electronic versions are widely available and integrated into electronic health records. Validated in 40+ languages and appropriate for children aged 4 and older (with child-specific wording) and adults.

2

Each item scores 1-5. Total ACT score is the sum of all 5 items, ranging 5-25. A higher score indicates better asthma control.

3

ACT score interpretation: ≤19 = asthma not well-controlled; 20-24 = asthma well-controlled; 25 = asthma completely controlled. Cutoff of 19/20 distinguishes controlled from uncontrolled asthma with high sensitivity and specificity. A change of ≥3 points is considered clinically significant. ACT scores correlate moderately with objective measures (FEV1, peak flow, nighttime awakening frequency) and are responsive to treatment changes.

Common pitfalls

  • Using ACT alone for asthma management—ACT guides symptom-based control assessment; combine with objective measures (FEV1, peak flow) and exacerbation frequency (GINA ABCD classification) for complete asthma risk stratification
  • Over-interpreting a single ACT 19 score—borderline control (ACT 19) may indicate either true suboptimal control or response variability; reassess after 2-4 weeks and during both stable and symptomatic periods
  • Ignoring ACT deterioration—a drop from ACT 24 to 20 signals emerging loss of control; investigate and treat promptly rather than waiting for further decline
  • Assuming ACT improvement reflects medication efficacy alone—improvement may follow allergen avoidance, environmental control, patient education, or natural disease remission; clinical context guides attribution
  • Failing to assess triggers—high ACT (controlled) in a patient with known allergen exposure suggests good pharmacotherapy but inadequate trigger management; address environmental and occupational triggers concurrently

Frequently asked questions

A patient has ACT 19 (not controlled) but FEV1 85% predicted. Should I escalate therapy?

Yes, likely. ACT <20 indicates symptomatic suboptimal control, which predicts exacerbation risk and impaired quality of life, regardless of FEV1. FEV1 85% is borderline low-normal. Consider escalation: if on no inhaled corticosteroid (ICS), initiate ICS; if on low-dose ICS, increase dose or add long-acting beta-agonist (LABA); if on ICS/LABA, ensure adherence, technique, and trigger control. Reassess ACT in 4-6 weeks.

What does a change of 3 points on the ACT mean?

A 3-point change (e.g., ACT 17 to 20) is the minimally important difference and represents clinically meaningful change in asthma control. Improvement indicates treatment benefit; deterioration indicates loss of control and need for reassessment and possible therapy adjustment.

Should I use ACT or ACQ (Asthma Control Questionnaire)?

Both are valid. ACT is shorter (5 items, 1-2 min), simpler, with clear cutoff (≥20 = controlled), preferred for routine primary care. ACQ is longer (6-7 items), more detailed, captures mild symptom variation better, preferred for research and specialist management of difficult asthma. Use ACT for screening and regular monitoring; ACQ for research or detailed asthma characterization.

Is ACT appropriate in ACOS (Asthma-COPD Overlap)?

Yes. ACT measures asthma control component of ACOS. However, ACOS patients may also have significant COPD burden (dyspnea, exacerbations) not fully captured by ACT. Combine ACT with CAT (COPD Assessment Test) or mMRC dyspnea scale for comprehensive assessment of both disease components.

Related methods

Sources

  1. Nathan, R. A., Sorkness, C. A., Kosinski, M., Schatz, M., Li, J. T., Marcus, P., ... & Pendergraft, T. B. (2004). Development of the asthma control test: A survey for assessing asthma control in children and adults. Allergy and Asthma Proceedings, 25(1), 1-6.

    Open DOI reference
    Copied.
  2. Schatz, M., Kosinski, M., Yarlas, A. S., Pendergraft, T. B., Kowgier, M., & Lee, J. H. (2012). The minimally important difference of the Asthma Control Test. Journal of Allergy and Clinical Immunology, 126(3), 581-587.e10.

    Open publication reference
    Copied.
  3. Juniper, E. F., O'Byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999). Development and validation of a questionnaire to measure asthma control. European Respiratory Journal, 14(4), 902-907.

    Open DOI reference
    Copied.